Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection

Paul Hengster, Mark D. Pescovitz, Debra Hyatt, Raimund Margreiter, Lars Bäckman, Francois Berthoux, Andrew Bradley, Ginny Bumgardner, James Burdick, Vincenzo Cambi, Gary Chan, Bernard Charpentier, Pierre Daloze, Henrik Ekberg, Göran Gannedahl, Robert Gaston, Phillip Halloran, Ian Hardie, Ingeborg Hauser, Robert JohnsonPaul Keown, Michèle Kessler, Bryce Kiberd, Robert Kirkman, Andrew Lazarovits, Arthur J. Matas, Ferdinand Mühlbacher, Bjorn Nashan, John Neylan, Nils Persson, Mark Pescovitz, Guiseppe Piccoli, Rudolf Pichlmayr, Claudio Ponticelli, Stuart Rodgers, Michael E. Shapiro, David Tiller, Gunnar Tufveson, Gunnar Tyden, Yves Vanrentergehm, Antonio Vercellone, Paul Vialtel, Flavio Vincenti, Samuel Weinstein, Alan Wilkinson

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV) infections in patients receiving a first cadaveric renal graft. In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. The onset of CMV disease was markedly delayed in the daclizumab groups in both studies. Daclizumab can effectively reduce the risk of acute rejection without causing a concomitant increase in opportunistic infections, and by decreasing the need for antirejection therapy may also have a beneficial effect on CMV infection rates.

Original languageEnglish
Pages (from-to)310-313
Number of pages4
JournalTransplantation
Volume68
Issue number2
DOIs
Publication statusPublished - Jul 27 1999

Fingerprint

Interleukin-2 Receptors
Cytomegalovirus Infections
Allografts
Kidney
Antibodies
Cytomegalovirus
Therapeutics
Incidence
Opportunistic Infections
Immunosuppressive Agents
Immunosuppression
Cyclosporine
Arm
Monoclonal Antibodies
daclizumab
Transplants

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Hengster, P., Pescovitz, M. D., Hyatt, D., Margreiter, R., Bäckman, L., Berthoux, F., ... Wilkinson, A. (1999). Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Transplantation, 68(2), 310-313. https://doi.org/10.1097/00007890-199907270-00028

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. / Hengster, Paul; Pescovitz, Mark D.; Hyatt, Debra; Margreiter, Raimund; Bäckman, Lars; Berthoux, Francois; Bradley, Andrew; Bumgardner, Ginny; Burdick, James; Cambi, Vincenzo; Chan, Gary; Charpentier, Bernard; Daloze, Pierre; Ekberg, Henrik; Gannedahl, Göran; Gaston, Robert; Halloran, Phillip; Hardie, Ian; Hauser, Ingeborg; Johnson, Robert; Keown, Paul; Kessler, Michèle; Kiberd, Bryce; Kirkman, Robert; Lazarovits, Andrew; Matas, Arthur J.; Mühlbacher, Ferdinand; Nashan, Bjorn; Neylan, John; Persson, Nils; Pescovitz, Mark; Piccoli, Guiseppe; Pichlmayr, Rudolf; Ponticelli, Claudio; Rodgers, Stuart; Shapiro, Michael E.; Tiller, David; Tufveson, Gunnar; Tyden, Gunnar; Vanrentergehm, Yves; Vercellone, Antonio; Vialtel, Paul; Vincenti, Flavio; Weinstein, Samuel; Wilkinson, Alan.

In: Transplantation, Vol. 68, No. 2, 27.07.1999, p. 310-313.

Research output: Contribution to journalArticle

Hengster, P, Pescovitz, MD, Hyatt, D, Margreiter, R, Bäckman, L, Berthoux, F, Bradley, A, Bumgardner, G, Burdick, J, Cambi, V, Chan, G, Charpentier, B, Daloze, P, Ekberg, H, Gannedahl, G, Gaston, R, Halloran, P, Hardie, I, Hauser, I, Johnson, R, Keown, P, Kessler, M, Kiberd, B, Kirkman, R, Lazarovits, A, Matas, AJ, Mühlbacher, F, Nashan, B, Neylan, J, Persson, N, Pescovitz, M, Piccoli, G, Pichlmayr, R, Ponticelli, C, Rodgers, S, Shapiro, ME, Tiller, D, Tufveson, G, Tyden, G, Vanrentergehm, Y, Vercellone, A, Vialtel, P, Vincenti, F, Weinstein, S & Wilkinson, A 1999, 'Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection', Transplantation, vol. 68, no. 2, pp. 310-313. https://doi.org/10.1097/00007890-199907270-00028
Hengster, Paul ; Pescovitz, Mark D. ; Hyatt, Debra ; Margreiter, Raimund ; Bäckman, Lars ; Berthoux, Francois ; Bradley, Andrew ; Bumgardner, Ginny ; Burdick, James ; Cambi, Vincenzo ; Chan, Gary ; Charpentier, Bernard ; Daloze, Pierre ; Ekberg, Henrik ; Gannedahl, Göran ; Gaston, Robert ; Halloran, Phillip ; Hardie, Ian ; Hauser, Ingeborg ; Johnson, Robert ; Keown, Paul ; Kessler, Michèle ; Kiberd, Bryce ; Kirkman, Robert ; Lazarovits, Andrew ; Matas, Arthur J. ; Mühlbacher, Ferdinand ; Nashan, Bjorn ; Neylan, John ; Persson, Nils ; Pescovitz, Mark ; Piccoli, Guiseppe ; Pichlmayr, Rudolf ; Ponticelli, Claudio ; Rodgers, Stuart ; Shapiro, Michael E. ; Tiller, David ; Tufveson, Gunnar ; Tyden, Gunnar ; Vanrentergehm, Yves ; Vercellone, Antonio ; Vialtel, Paul ; Vincenti, Flavio ; Weinstein, Samuel ; Wilkinson, Alan. / Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. In: Transplantation. 1999 ; Vol. 68, No. 2. pp. 310-313.
@article{99ad2b3294914e2e874955ea1c04a667,
title = "Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection",
abstract = "Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV) infections in patients receiving a first cadaveric renal graft. In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. The onset of CMV disease was markedly delayed in the daclizumab groups in both studies. Daclizumab can effectively reduce the risk of acute rejection without causing a concomitant increase in opportunistic infections, and by decreasing the need for antirejection therapy may also have a beneficial effect on CMV infection rates.",
author = "Paul Hengster and Pescovitz, {Mark D.} and Debra Hyatt and Raimund Margreiter and Lars B{\"a}ckman and Francois Berthoux and Andrew Bradley and Ginny Bumgardner and James Burdick and Vincenzo Cambi and Gary Chan and Bernard Charpentier and Pierre Daloze and Henrik Ekberg and G{\"o}ran Gannedahl and Robert Gaston and Phillip Halloran and Ian Hardie and Ingeborg Hauser and Robert Johnson and Paul Keown and Mich{\`e}le Kessler and Bryce Kiberd and Robert Kirkman and Andrew Lazarovits and Matas, {Arthur J.} and Ferdinand M{\"u}hlbacher and Bjorn Nashan and John Neylan and Nils Persson and Mark Pescovitz and Guiseppe Piccoli and Rudolf Pichlmayr and Claudio Ponticelli and Stuart Rodgers and Shapiro, {Michael E.} and David Tiller and Gunnar Tufveson and Gunnar Tyden and Yves Vanrentergehm and Antonio Vercellone and Paul Vialtel and Flavio Vincenti and Samuel Weinstein and Alan Wilkinson",
year = "1999",
month = "7",
day = "27",
doi = "10.1097/00007890-199907270-00028",
language = "English",
volume = "68",
pages = "310--313",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection

AU - Hengster, Paul

AU - Pescovitz, Mark D.

AU - Hyatt, Debra

AU - Margreiter, Raimund

AU - Bäckman, Lars

AU - Berthoux, Francois

AU - Bradley, Andrew

AU - Bumgardner, Ginny

AU - Burdick, James

AU - Cambi, Vincenzo

AU - Chan, Gary

AU - Charpentier, Bernard

AU - Daloze, Pierre

AU - Ekberg, Henrik

AU - Gannedahl, Göran

AU - Gaston, Robert

AU - Halloran, Phillip

AU - Hardie, Ian

AU - Hauser, Ingeborg

AU - Johnson, Robert

AU - Keown, Paul

AU - Kessler, Michèle

AU - Kiberd, Bryce

AU - Kirkman, Robert

AU - Lazarovits, Andrew

AU - Matas, Arthur J.

AU - Mühlbacher, Ferdinand

AU - Nashan, Bjorn

AU - Neylan, John

AU - Persson, Nils

AU - Pescovitz, Mark

AU - Piccoli, Guiseppe

AU - Pichlmayr, Rudolf

AU - Ponticelli, Claudio

AU - Rodgers, Stuart

AU - Shapiro, Michael E.

AU - Tiller, David

AU - Tufveson, Gunnar

AU - Tyden, Gunnar

AU - Vanrentergehm, Yves

AU - Vercellone, Antonio

AU - Vialtel, Paul

AU - Vincenti, Flavio

AU - Weinstein, Samuel

AU - Wilkinson, Alan

PY - 1999/7/27

Y1 - 1999/7/27

N2 - Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV) infections in patients receiving a first cadaveric renal graft. In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. The onset of CMV disease was markedly delayed in the daclizumab groups in both studies. Daclizumab can effectively reduce the risk of acute rejection without causing a concomitant increase in opportunistic infections, and by decreasing the need for antirejection therapy may also have a beneficial effect on CMV infection rates.

AB - Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV) infections in patients receiving a first cadaveric renal graft. In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. The onset of CMV disease was markedly delayed in the daclizumab groups in both studies. Daclizumab can effectively reduce the risk of acute rejection without causing a concomitant increase in opportunistic infections, and by decreasing the need for antirejection therapy may also have a beneficial effect on CMV infection rates.

UR - http://www.scopus.com/inward/record.url?scp=0033609459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033609459&partnerID=8YFLogxK

U2 - 10.1097/00007890-199907270-00028

DO - 10.1097/00007890-199907270-00028

M3 - Article

C2 - 10440409

AN - SCOPUS:0033609459

VL - 68

SP - 310

EP - 313

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -